Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record.

Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra‐pancreatic glucose regulation

Ortiz‐Andrade, R. R, Sánchez‐Salgado, J. C., Navarrete‐Vázquez, G., Webster, S. P., Binnie, M., García‐Jiménez, S., León‐Rivera, I., Cigarroa‐Vázquez, P., Villalobos‐Molina, R., Estrada‐Soto, S.·2008·Diabetes, Obesity and Metabolism

Abstract

Aim: The present investigation was designed to determine the in vivo antidiabetic effect of naringenin (NG) in normoglycaemic and diabetic rat models through blood glucose (GLU) measurements following acute and subchronic time periods. Possible modes of action of NG were investigated and its acute toxicity determined. Methods: Normoglycaemic and non‐insulin‐dependent diabetes mellitus (NIDDM) rat models were treated for acute and subchronic (5 days) time periods with 50 mg/kg/day of NG. Blood biochemical profiles were determined after 5 days of the treatment in normoglycaemic and NIDDM rats using commercial kits for GLU, triglycerides (TG), total cholesterol (CHOL) and high‐density lipoprotein (HDL). In order to elucidate its antidiabetic mode of action, NG was administered intragastrically and an oral glucose tolerance test performed using GLU and sucrose (2 g/kg) as substrates. The inhibitory effect of a single concentration of NG (10 μM) on 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) activity in vitro was determined. Finally, the preclinical safety and tolerability of NG was determined by toxicological evaluation in mice and rats using Organization for Economic Cooperation and Development (OECD) protocols. Results: Intragastrically administered NG (50 mg/kg) induced a significant decrease in plasma GLU in normoglycaemic and NIDDM rat models (p < 0.05) following acute and subchronic time periods. After 5 days of administration, NG produced significant diminished blood GLU and TG levels in streptozotocin–nicotinamide–induced diabetic rats. The administration of NG to normal rats significantly increased the levels of TG, CHOL and HDL (p < 0.05). NG (5 and 50 mg/kg) induced a total suppression in the increase of plasma GLU levels after administration of substrates (p < 0.01), but NG did not produce inhibition of α‐glucosidase activity in vitro . However, NG (10 μM) was shown to inhibit 11β‐HSD1 activity by 39.49% in a cellular enzyme assay. Finally, NG showed a Medium Lethal Dose LD 50 > 5000 mg/kg and ranking at level five based on OECD protocols. Conclusion: Our findings suggest that NG may exert its antidiabetic effect by extra‐pancreatic action and by suppressing carbohydrate absorption from intestine, thereby reducing the postprandial increase in blood GLU levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00869.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 178

Metadata

Authors
Ortiz‐Andrade, R. R., Sánchez‐Salgado, J. C., Navarrete‐Vázquez, G., Webster, S. P., Binnie, M., García‐Jiménez, S., León‐Rivera, I., Cigarroa‐Vázquez, P., Villalobos‐Molina, R., & Estrada‐Soto, S.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-10-14
Volume
10
Issue
11
Pages
1097-1104
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2165809374
Cited by
178
References
0
FWCI
2.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra‐pancreatic glucose regulation. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00869.x
The paper
Ortiz‐Andrade, R. R., Sánchez‐Salgado, J. C., Navarrete‐Vázquez, G., Webster, S. P., Binnie, M., García‐Jiménez, S., León‐Rivera, I., Cigarroa‐Vázquez, P., Villalobos‐Molina, R., & Estrada‐Soto, S. (2008). Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra‐pancreatic glucose regulation. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00869.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.